Literature DB >> 6117072

Opiates inhibit adenylate cyclase by stimulating GTP hydrolysis.

G Koski, W A Klee.   

Abstract

Specific, GTP hydrolysis catalyzed by membranes prepared from neuroblastoma--glioma (NG108-15) hybrid cells can be measured in the presence of adenosine-5'-[beta, gamma-imido] triphosphate (p[NH]ppA), ATP, and a nucleotide triphosphate-regenerating system. Opiates and opioid peptides stimulate low Km GTP hydrolysis when measured in the presence of Na+ and Mg2+. Opiate stimulation is rapid, stereospecific, and reserved by the antagonist naloxone. Potencies of opiates as stimulators of GTP hydrolysis and as inhibitors of adenylate cyclase are closely correlated. Agents that stimulate adenylate cyclase, including prostaglandin E1, 2-Cl-adenosine, secretin, and NaF, have little or no effect upon the rate of GTP hydrolysis. Opiates have no effect upon either adenylate cyclase or GTPase activity in membranes prepared from C6-BU1 glioma cells, which lack opiate receptors. In view of the pivotal role of GTP in the activation of adenylate cyclase, we conclude that receptor-mediated stimulation of GTP hydrolysis is the mechanism by which opiates and other inhibitory hormones lower adenylate cyclase activity in NG108-15 cell membranes.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6117072      PMCID: PMC319753          DOI: 10.1073/pnas.78.7.4185

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

Review 1.  Structural, electrophysiological, biochemical, and pharmacological properties of neuroblastoma-glioma cell hybrids in cell culture.

Authors:  B Hamprecht
Journal:  Int Rev Cytol       Date:  1977

2.  Morphine receptors as regulators of adenylate cyclase activity.

Authors:  S K Sharma; M Nirenberg; W A Klee
Journal:  Proc Natl Acad Sci U S A       Date:  1975-02       Impact factor: 11.205

3.  Activation of turkey erythrocyte adenylate cyclase and blocking of the catecholamine-stimulated GTPase by guanosine 5'-(gamma-thio) triphosphate.

Authors:  D Cassel; Z Selinger
Journal:  Biochem Biophys Res Commun       Date:  1977-08-08       Impact factor: 3.575

4.  The regulatory GTPase cycle of turkey erythrocyte adenylate cyclase.

Authors:  D Cassel; H Levkovitz; Z Selinger
Journal:  J Cyclic Nucleotide Res       Date:  1977-12

5.  Reversible activation of hepatic adenylate cyclase by guanyl-5'-yl-(alpha,beta-methylene)diphosphonate and guanyl-5'-yl imidodiphosphate.

Authors:  C Londos; M C Lin; A F Welton; P M Lad; M Rodbell
Journal:  J Biol Chem       Date:  1977-08-10       Impact factor: 5.157

6.  The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. V. An obligatory role of guanylnucleotides in glucagon action.

Authors:  M Rodbell; L Birnbaumer; S L Pohl; H M Krans
Journal:  J Biol Chem       Date:  1971-03-25       Impact factor: 5.157

7.  Mechanism of adenylate cyclase activation by cholera toxin: inhibition of GTP hydrolysis at the regulatory site.

Authors:  D Cassel; Z Selinger
Journal:  Proc Natl Acad Sci U S A       Date:  1977-08       Impact factor: 11.205

8.  A neuroblastoma times glioma hybrid cell line with morphine receptors.

Authors:  W A Klee; M Nirenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1974-09       Impact factor: 11.205

9.  Catecholamine-stimulated GTPase activity in turkey erythrocyte membranes.

Authors:  D Cassel; Z Selinger
Journal:  Biochim Biophys Acta       Date:  1976-12-08

10.  Opiate-dependent modulation of adenylate cyclase.

Authors:  S K Sharma; W A Klee; M Nirenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1977-08       Impact factor: 11.205

View more
  40 in total

1.  Measurement of agonist-induced guanine nucleotide turnover by the G-protein Gi1alpha when constrained within an alpha2A-adrenoceptor-Gi1alpha fusion protein.

Authors:  A Wise; I C Carr; G Milligan
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

2.  Inhibition of the GTPase activity of transducin by an NAD+:arginine ADP-ribosyltransferase from turkey erythrocytes.

Authors:  P A Watkins; Y Kanaho; J Moss
Journal:  Biochem J       Date:  1987-12-15       Impact factor: 3.857

3.  Reconstitution of high-affinity opioid agonist binding in brain membranes.

Authors:  A E Remmers; F Medzihradsky
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

4.  Delta-opioid-receptor-mediated inhibition of adenylate cyclase is transduced specifically by the guanine-nucleotide-binding protein Gi2.

Authors:  F R McKenzie; G Milligan
Journal:  Biochem J       Date:  1990-04-15       Impact factor: 3.857

5.  Interactions of the alpha2A-adrenoceptor with multiple Gi-family G-proteins: studies with pertussis toxin-resistant G-protein mutants.

Authors:  A Wise; M A Watson-Koken; S Rees; M Lee; G Milligan
Journal:  Biochem J       Date:  1997-02-01       Impact factor: 3.857

6.  Bradykinin-activated transmembrane signals are coupled via No or Ni to production of inositol 1,4,5-trisphosphate, a second messenger in NG108-15 neuroblastoma-glioma hybrid cells.

Authors:  H Higashida; R A Streaty; W Klee; M Nirenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

Review 7.  Techniques used in the identification and analysis of function of pertussis toxin-sensitive guanine nucleotide binding proteins.

Authors:  G Milligan
Journal:  Biochem J       Date:  1988-10-01       Impact factor: 3.857

8.  Foetal-calf serum stimulates a pertussis-toxin-sensitive high-affinity GTPase activity in rat glioma C6 BU1 cells.

Authors:  G Milligan
Journal:  Biochem J       Date:  1987-07-15       Impact factor: 3.857

9.  Hemodynamic response to naloxone during live Escherichia coli sepsis in splenectomized dogs.

Authors:  M Rees; J C Bowen
Journal:  Ann Surg       Date:  1984-11       Impact factor: 12.969

10.  Ultra-low dose naltrexone attenuates chronic morphine-induced gliosis in rats.

Authors:  Theresa-Alexandra M Mattioli; Brian Milne; Catherine M Cahill
Journal:  Mol Pain       Date:  2010-04-16       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.